Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk
1. From baseline to 52 weeks, tirzepatide resulted in a greater reduction in mean HbA1c levels compared to insulin glargine. ...
1. From baseline to 52 weeks, tirzepatide resulted in a greater reduction in mean HbA1c levels compared to insulin glargine. ...
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.